Neonatology

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

Retrieved on: 
fredag, maj 17, 2024
Research, Baby, Maternity, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Patient, Disease, Bronchopulmonary dysplasia, OHB, Clinical trial, Trial of the century, Safety, Premature, BPD, Place of birth, Neonatology

"As a neonatologist, I’m thrilled that we have restarted this groundbreaking clinical trial previously paused during the out-licensing process to Oak Hill Bio.

Key Points: 
  • "As a neonatologist, I’m thrilled that we have restarted this groundbreaking clinical trial previously paused during the out-licensing process to Oak Hill Bio.
  • OHB-607 can potentially improve the outcomes for infants born extremely premature," said Victoria Niklas, Chief Medical Officer at Oak Hill Bio.
  • “At Oak Hill Bio, we are committed to advancing the field of neonatology and delivering the best possible care and outcomes to patients together with our partners at Chiesi."
  • “The restart of this study marks a significant milestone highlighting the shared commitment of Chiesi and Oak Hill Bio to advance solutions for the vulnerable group of extremely premature infants,” commented Diego Ardigò, Global Research & Development Head at Chiesi Group.

Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges

Retrieved on: 
tisdag, maj 14, 2024
Partnership, Patient, Drug, Organization, Health, Respiratory disease, Drug development, Premature, Research, Competence, Neonatology, Pharmaceutical industry

PARMA, Italy, May 14, 2024 /PRNewswire/ -- Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a memorandum of understanding with Karolinska Institutet, a medical university.

Key Points: 
  • PARMA, Italy, May 14, 2024 /PRNewswire/ -- Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a memorandum of understanding with Karolinska Institutet, a medical university.
  • The agreement solidifies a commitment between the two organizations to collaborate on joint efforts aimed at advancing therapeutic solutions for urgent health challenges.
  • The landmark collaboration between Chiesi and Karolinska Institutet (KI), will accelerate research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other specialty care indications.
  • Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions.

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Retrieved on: 
måndag, april 22, 2024
Carbon, Science, Corporation, Enzyme replacement therapy, FDA, AIR, License, International, RARE, Investment, Climate, Fabry disease, Climate change, CER, B Corporation (certification), CDP, Partnership, Empowerment, Alpha-mannosidosis, Parent, CARE, Chronic obstructive pulmonary disease, Environment, Culture, Benefit corporation, Patient, Science Based Targets initiative, Bronchiectasis, Acquisition, Caregiver, Epidermolysis bullosa, GHG, Place of birth, Health, Neonatology, Ethics, Asthma, RDS, Infant respiratory distress syndrome, Growth, Carbon Disclosure Project, COPD, Pharmaceutical industry

PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet.

Key Points: 
  • Chiesi's fixed triple formulation for the treatment of asthma and COPD (Chronic Obstructive Pulmonary Disease) achieved a 27% @CER growth.
  • Also, in 2023 it was introduced in China, presenting a pivotal opportunity for growth and expanding access to treatment for more patients.
  • In March 2023, Chiesi enriched its AIR portfolio thanks to the partnership with Affibody AB to develop and commercialize innovative treatments for respiratory diseases.
  • In November 2023, Chiesi signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel solution for bronchiectasis.

Star Gala inspires $2.3 million in giving to support Children's Minnesota neuroscience program and first-of-its kind pediatric surgery suite

Retrieved on: 
torsdag, april 18, 2024
Brain, UnitedHealth Group, Cancer, KARE, Hope, Star Gala, Great Clips, Kid, Minneapolis–Saint Paul, Injury, Nervous system, Concussion, Epilepsy, Trust, Neonatology

MINNEAPOLIS and ST. PAUL, Minn., April 18, 2024 /PRNewswire/ -- Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program .

Key Points: 
  • MINNEAPOLIS and ST. PAUL, Minn., April 18, 2024 /PRNewswire/ -- Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program .
  • Star Gala is regarded as one of the biggest nights of the year for the Twin Cities philanthropic community.
  • Donations also supported The Richard M. Schulze Family Foundation iMRI Surgical Suite , a state-of-the-art surgery facility at Children's Minnesota that is the first of its kind in North America.
  • Star Gala was made possible by presenting sponsor APi Group with additional support from Best Buy, Co. Inc., Great Clips and UnitedHealth Group.

Royal Farms Demonstrates Commitment to Community with $150,000 Donation to Johns Hopkins Children's Center

Retrieved on: 
onsdag, mars 13, 2024
Royal Farms, Health, Coin, Organization, Johns Hopkins Children's Center, Neurology, Cardiology, Partnership, Patient, Farm, Hope, Operation, Neonatology, Hospital

BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.

Key Points: 
  • BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.
  • Since 1994, Royal Farms has collected over $3 million in coins from spare change donated from customers and provided it to Johns Hopkins Children’s Center to show our dedication to supporting children's health and well-being in the community.
  • "Royal Farms is honored to support the incredible work being done at Johns Hopkins Children's Center," said Jeff Mengel, Vice President of Operations at Royal Farms.
  • "We are incredibly grateful for Royal Farms' generous donation and ongoing support," said Jennifer Phelps at Johns Hopkins Children's Center.

BayCare Reveals Plans for New Hospital in Manatee County

Retrieved on: 
onsdag, april 3, 2024
I-275, Health, MRI, Growth, Central Florida, Urology, Bed, Cardiology, Patient, I-75, Hospital, Mammography, Obstetrics, Physician, Neonatology, Gastroenterology

CLEARWATER, Fla., April 3, 2024 /PRNewswire/ -- BayCare Health System announced construction plans today for its newest hospital, a comprehensive acute care facility to serve the rapidly growing community of Manatee County. BayCare Hospital Manatee will be the county's first not-for-profit hospital and the only hospital north of Manatee River.

Key Points: 
  • CLEARWATER, Fla., April 3, 2024 /PRNewswire/ -- BayCare Health System announced construction plans today for its newest hospital, a comprehensive acute care facility to serve the rapidly growing community of Manatee County.
  • BayCare Hospital Manatee will be the county's first not-for-profit hospital and the only hospital north of Manatee River.
  • BayCare Hospital Manatee will be the county's first not-for-profit hospital.
  • BayCare anticipates opening the hospital, its 17th, in 2027 with 154 beds in private patient rooms.

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Retrieved on: 
måndag, februari 5, 2024
Molecule, Euronext, Inflammation, Galapagos NV, CMO, Novartis, FMH, Maralixibat chloride, Patient, IPO, Disease, Neonatology, University, NLRP3, Pharmaceutical industry

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Key Points: 
  • NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
    BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today.
  • With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader.
  • Earlier in his career, Thomas served in key leadership roles in clinical and medical assessment, business development and market access at Novartis.
  • Alan Watt, Chief Executive Officer of NodThera, said: “We are delighted to welcome Thomas to the NodThera team, with his wealth of sector experience and successful execution of drug development programs across multiple therapeutic areas.

Cincinnati Children's Elevates Care for Pregnant Women with Complex Fetal Conditions

Retrieved on: 
fredag, januari 26, 2024
Hope, Woman, Patient, TriHealth, Mother, Neonatology, Test management, Nursing, News, Pregnancy, Prenatal care, Education

CINCINNATI, Jan. 26, 2024 /PRNewswire/ -- Cincinnati Children's announces the opening of a new antepartum unit within the Fetal Care Center .

Key Points: 
  • CINCINNATI, Jan. 26, 2024 /PRNewswire/ -- Cincinnati Children's announces the opening of a new antepartum unit within the Fetal Care Center .
  • "These rooms have been strategically placed in the hospital to provide pregnant women the best quality care and close proximity to any sophisticated fetal surgeries they may need leading up to birth," said Foong-Yen Lim, MD, Surgical Director, Cincinnati Children's Fetal Care Center.
  • The antepartum unit allows pregnant women to receive care needed to prolong their pregnancy, reducing risks and enhancing outcomes for their babies.
  • Differentiating itself from other fetal care clinics, Cincinnati Children's Fetal Care Center employs highly skilled nurses from TriHealth to provide compassionate, comforting care to expecting mothers before and after delivery.

CHOP Celebrates Second Anniversary of Middleman Family Pavilion Opening

Retrieved on: 
fredag, januari 26, 2024
Patient, CHOP, Children's Hospital of Philadelphia, Operating, Medicine, Growth, PICU, Tertiary referral hospital, Hospital, Adolescence, Neonatology

PHILADELPHIA, Jan. 26, 2024 /PRNewswire/ -- Today, Children's Hospital of Philadelphia (CHOP) celebrates the second anniversary of the opening of the Middleman Family Pavilion, CHOP's hospital location in King of Prussia, PA. Since the Middleman Family Pavilion opened in January of 2022, over 130,000 patients have been treated on CHOP's King of Prussia Campus.

Key Points: 
  • -- The Middleman Family Pavilion, CHOP's second inpatient location in King of Prussia, continues to provide families access to more of CHOP's best-in-class care –
    PHILADELPHIA, Jan. 26, 2024 /PRNewswire/ -- Today, Children's Hospital of Philadelphia (CHOP) celebrates the second anniversary of the opening of the Middleman Family Pavilion , CHOP's hospital location in King of Prussia, PA.
  • Since the Middleman Family Pavilion opened in January of 2022, over 130,000 patients have been treated on CHOP's King of Prussia Campus.
  • Staffed 24/7 by a core team of Neonatologists and Advanced Practice Providers, the unit provides comprehensive care with additional non-urgent surgical capabilities.
  • "We are proud and excited about the growth and expansion of services at the Middleman Family Pavilion in the last two years," said Cheryl Gebeline-Myers, Vice President of Operations, Children's Hospital of Philadelphia's Middle Family Pavilion in King of Prussia.

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Retrieved on: 
tisdag, januari 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Development, Guggenheim Partners, BPD, Mother, Neonatology, Gestational age, Place of birth, License, Risk, Disease, Premature, Bronchopulmonary dysplasia, Pharmaceutical industry

OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.

Key Points: 
  • OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.
  • For the developing fetus, mothers are the primary source of IGF-1.
  • Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD1.
  • Their deep expertise in neonatology will help to rapidly advance this promising therapy to patients.”
    Guggenheim Securities LLC acted as exclusive financial advisor to Oak Hill Bio and Goodwin Procter LLP served as its legal advisor.